The role of 25-hydroxyvitamin D in insulin resistance and inflammation in patients with Chronic Kidney Disease: A randomised controlled trial.

Not Applicable

Completed

• Conditions: Chronic Kidney Disease Stage 3; Vitamin D deficiency; Metabolic and Endocrine - Metabolic disorders; Inflammatory and Immune System - Other inflammatory or immune system disorders

• Registration Number: ACTRN12609000246280
• Lead Sponsor: A/Prof Nicole Isbel

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-05-12
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 51

Inclusion Criteria

Chronic Kidney Disease (CKD) stage 3 (estimated glomerular filtration rate (eGFR)20-59ml/min/1.73m2, calculated using Modified Diet in Renal Disease (MDRD) formula). Age 18 or over.

Exclusion Criteria

Unable or unwilling to give informed consent. Estimated glomerular filtration rate <20 or >60ml/min/1.73m2. Life expectancy less than 6 months. Predicted to start dialysis within 6 months. Current involvement in other research study. Organ transplant recipient. Active inflammatory/infectious process or recent (<1 month) use of anti-inflammatory drugs. Use of oral hypoglycaemic medication. Current or recent (<3 months prior) use of; vitamin D products, glucocorticoids, anti-convulsants, barbiturates, hormone therapy. Chronic or active pathology resulting in liver or pancreatic disease. Malabsorptive state or lactose intolerant. Active endocrine disorder; thyrotoxicosis, Cushing’s, acromegaly,phaeochromocytoma. Serum corrected calcium >2.54mmol/L. Serum phosphate >1.49mmol/

Study & Design

• Study Type: Interventional
• Study Design: Not specified